

Supplemental Material

Table S1. Demographics of pre-pandemic healthy volunteers used for the determination of VIDAS®

SARS-CoV-2 IgM and IgG specificity

VIDAS® SARS-CoV-2 serology testing	IgM	IgG	Combined IgM/IgG
Study population, N (%)	308 (100%)	989 (100%)	308 (100%)
Age in years, median (range)	45 (18-86)	44 (18-86)	45 (18-86)
Gender, N (%)			
Male	143 (46.4%)	347 (35.1%)	143 (46.4%)
Female	165 (53.6%)	642 (64.9%)	165 (53.6%)
Pre-pandemic healthy volunteers, N (%)			
France	161 (52.3%)	842 (85.1%)	161 (52.3%)
United States	147 (47.7%)	147 (14.9%)	147 (47.7%)

Table S2. Demographics of French patients positive for SARS-CoV-2 used for the determination of VIDAS® SARS-CoV-2 IgM and IgG sensitivity (positive percent agreement with RT-PCR positivity)

VIDAS® SARS-CoV-2 serology testing	IgM	IgG	Combined IgM/IgG
Patients with documented date of RT-PCR-positive test			
Number of samples tested	234	253	232
Study population, N (%)	132 (100%)	139 (100%)	130 (100%)
Age in years, median (range)			
Non-hospitalized (N=61)	missing	missing	missing
Other (N=71/78/69)	71 (27-96)	70.5 (27-96)	70 (27-96)
Gender, N (%)			
Male	47 (35.6%)	53 (38.1%)	47 (36.2%)
Female	24 (18.2%)	25 (18.0%)	22 (16.9%)
Missing	61 (46.2%)	61 (43.9%)	61 (46.9%)
Disease severity, N (%)			
Hospitalized	56 (42.4%)	57 (41.0%)	54 (41.55%)
Non-hospitalized	61 (46.2%)	61 (43.9%)	61 (46.9%)
Missing	15 (11.4%)	21 (15.1%)	15 (11.55%)
Patients with documented date of symptom onset			
Number of samples tested	108	113	105
Study population, N (%)	65 (100%)	71 (100%)	63 (100%)
Age in years, median (range)	70 (27-96)	70 (27-96)	70 (27-96)
Gender, N (%)			
Male	45 (69.2%)	51 (71.8%)	45 (71.4%)
Female	20 (30.8%)	20 (28.2%)	18 (28.6%)
Disease severity, N (%)			
Hospitalized	50 (76.9%)	50 (70.4%)	48 (76.2%)
Non-hospitalized ^a	0 (0.00%)	0 (0.0%)	0 (0.0%)
Missing	15 (23.1%)	21 (29.6%)	15 (23.8%)

^aDate of symptom onset not documented in non-hospitalized COVID-19 patients

Table S3. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM and IgG test results according to the time from RT-PCR-positive test result (all available samples)

VIDAS® SARS-CoV-2 serology testing	Time from RT-PCR-positive result	Median (range) time in days	No. samples^a	No. positive results	PPA	95% CI
IgM (N=234)^b	0-7 days	1.5 (0-7)	112	51	45.5%	36.6-54.8%
	8-15 days	14 (8-15)	60	49	81.7%	70.1-89.4%
	16-23 days	20 (16-23)	38	31	81.6%	66.6-90.8%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	9	81.8%	52.3-94.9%
IgG (N=253)^b	0-7 days	1 (0-7)	115	47	40.9%	32.3-50.0%
	8-15 days	14 (8-15)	73	63	86.3%	76.6-92.4%
	16-23 days	20 (16-23)	41	39	95.1%	83.5-99.4%
	24-31 days	26 (24-28)	13	13	100.0%	75.3-100.0%
	≥ 32 days	33 (32-65)	11	11	100.0%	71.5-100.0%

^ano more than one test result per patient per time period; ^bPPA (95% CI) for common samples (N=232) are shown in Table 4

Table S4. Positive percent agreement (PPA) of the VIDAS® SARS-CoV-2 IgM and IgG test results according to the time from symptom onset (all available samples)

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	Median (range) time in days	No. samples^a	No. positive results	PPA	95% CI
IgM (N=108)^b	0-7 days	6 (1-7)	24	9	37.5%	21.2-57.3%
	8-15 days	12 (8-15)	29	24	82.8%	65.5-92.4%
	16-23 days	18 (16-23)	26	26	100.0%	86.8-100.0%
	24-31 days	26 (24-30)	18	18	100.0%	81.5-100.0%
	≥ 32 days	34 (32-65)	11	11	100.0%	71.5-100.0%
IgG (N=113)^b	0-7 days	5.5 (1-7)	24	9	37.5%	21.2-57.3%
	8-15 days	12 (8-15)	31	25	80.6%	63.7-90.8%
	16-23 days	18 (16-23)	29	28	96.6%	82.2-99.9%
	24-31 days	26 (24-30)	19	18	94.7%	75.4-99.1%
	≥ 32 days	35 (32-65)	10	10	100.0%	69.2-100.0%

^ano more than one test result per patient per time period; ^bPPA (95% CI) for common samples (N=105) are shown in Table 5

Table S5. Positive and negative predictive values (PPV/NPV) at 5% prevalence of the VIDAS® SARS-CoV-2 IgM, IgG and combined IgM/IgG test results, according to the time from symptom onset (all available samples for IgG specificity)

VIDAS® SARS-CoV-2 serology testing	Time from symptom onset	PPV ^a (95% CI)	NPV ^a (95% CI)
IgM	0-7 days	72.1% (36.3-92.1%)	96.5% (95.4-97.4%)
	8-15 days	87.0% (62.5-96.4%)	99.1% (98.0-99.6%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b
IgG	0-7 days	94.3% (68-99.2%)	96.5% (95.4-97.4%)
	8-15 days	97.8% (86.3-99.7%)	99.3% (98.2-99.7%)
	16-23 days	98.0% (87.6-99.7%)	99.8% (98.6-100.0%)
	24-31 days	98.0% (87.4-99.7%)	99.7% (98.1-100.0%)
	≥ 32 days	98.1% (88-99.7%)	100.0% (N/A) ^b
Combined IgM/IgG	0-7 days	74.7% (40-92.9%)	96.7% (95.6-97.6%)
	8-15 days	87.9% (64.5-96.7%)	99.5% (98.4-99.8%)
	16-23 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b
	24-31 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b
	≥ 32 days	89.0% (67.1-97.0%)	100.0% (N/A) ^b

^aPPV and NPV were calculated at 5% prevalence using values of sensitivity (PPA) determined on paired IgM and IgG test results (N=105; Table 5); values of specificity were those calculated on all available samples (N=308 for IgM and N=989 for IgG; Table 3); ^b95% CI not calculable (division by zero)